MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 07/16/24
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific SessionsGlobeNewsWire • 06/22/24
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific SessionsGlobeNewsWire • 06/05/24
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind CorporationPRNewsWire • 05/29/24
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With PulmatrixGlobeNewsWire • 05/29/24
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateGlobeNewsWire • 05/08/24
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewsWire • 05/06/24
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024GlobeNewsWire • 05/01/24
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesGlobeNewsWire • 04/30/24
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewsWire • 04/29/24
INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsGlobeNewsWire • 03/11/24
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8GlobeNewsWire • 03/05/24
Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 EarningsZacks Investment Research • 02/28/24
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateGlobeNewsWire • 02/27/24
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024GlobeNewsWire • 02/20/24
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®GlobeNewsWire • 02/15/24